Pfizer is selling its remaining stake in COVID-19 vaccine partner BioNTech.
The U.S. drugmaker is offering about 4.55 million American depositary receipts in an overnight block trade, marketed at between $108 and $111.70 per share, according to a Nov. 13 report from Bloomberg. At the high end of the range, the stake sale is valued at approximately $508 million.
Pfizer and BioNTech collaborated in 2020 to develop a COVID-19 vaccine, one of the pandemic’s most profitable products. Though the companies continue to work together on vaccine formulations, Pfizer’s equity interest in BioNTech was part of their initial partnership.
BioNTech’s U.S.-listed shares fell 3.6%, while Pfizer’s dropped about 0.2%.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
